Evaluation of fluticasone propionate (500 μg day−1) administered either as dry powder via a Diskhaler® inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 μg day−1) administered by pressurized inhaler

Bo Lundbäck(Unknown), A.L. Jones, Jean‐Louis Hébert(Centre hospitalier de l'Université Laval), Michael J. Alexander(Los Angeles Medical Center), Steven Kesten(Toronto Western Hospital), R. Van Uffelen, James Day(Kingston General Hospital), Ralf J. Holzer

Respiratory Medicine

November 1, 1993

10.1016/s0954-6111(05)80264-1

Cited by 107

Related Papers

Recommendations on Angiographic Revascularization Grading Standards for Acute Ischemic Stroke

|Stroke|2013|1.7k

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria

|Allergy|2018|1.4k

The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

|Allergy|2014|1.2k

Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE

|Allergy|2004|1.1k

Chronic rhinosinusitis in Europe - an underestimated disease. A GA2LEN study

|Allergy|2011|1.1k